Status: Recruiting

A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.

Participants needed: 15

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Atridia Pty Ltd.Updated: Aug 11, 2026Locations: 6

Eligibility criteria

Ability to understand the trial procedures and possible adverse events, voluntar... [+3]

Plan to receive any other anti-tumor therapy during the study. [+8]

Status: Recruiting

A Trial of HRS-3095 in Healthy Volunteers

The purpose of this study is to assess safety, PK, Pharmacodynamic profile of a single dose of HRS-3095 in healthy participants

Participants needed: 36

Trial details

Phase: Early Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Atridia Pty Ltd.Updated: Aug 7, 2026Locations: 1

Eligibility criteria

Male or female aged between 18 years and 55 years (inclusive) [+3]

History or evidence of clinically significant disorders. [+5]

Status: Recruiting

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.

Participants needed: 25

Trial details

Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: Atridia Pty Ltd.Updated: Jan 15, 2026Locations: 11

Eligibility criteria

Adequate bone marrow and other vital organ functions [+2]

Plan to receive any other anti-tumor therapy during the study. [+7]